A Study to Learn About mRNA Vaccines Against Influenza in Adults
← catalyst calendarNCT07431853 · readout in 306 d
Sponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Prevention
Enrollment
770estimated
Sites
15
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-02-23 | actual | When the study began enrolling |
| Primary completion | 2027-06-22 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-06-22 | estimated | The whole study's end, after follow-up |
| First posted | 2026-02-25 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-06 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Healthy Adults
Interventions
- Biological: Vaccine Candidate #1
- Biological: Vaccine Candidate #2
- Biological: Vaccine Candidate #3
- Biological: Vaccine Candidate #4
- Biological: Vaccine Candidate #5
- Biological: Vaccine Candidate #6
- Biological: TIV1 or TIV2
Primary outcomes
what the primary-completion date above is the date OFPercentage of participants reporting prespecified local reactions following vaccination
measured Within 7 days after vaccination
Percentage of participants reporting prespecified systemic events following vaccination.
measured Within 7 days after vaccination
Percentage of participants reporting adverse events (AEs) following vaccination.
measured Within 1 month after vaccination
Percentage of participants reporting serious adverse events (SAEs) following vaccination.
measured Within 6 months after vaccination
Percentage of participants reporting newly diagnosed chronic medical conditions (NDCMCs) following vaccination.
measured Within 6 months after vaccination
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed